Market Insights Health Hospitals Inpatient Care

Treatment of Cardiovascular Diseases - China

China

In the year 2024, the revenue in the Treatment of Cardiovascular Diseases market in China is estimated to reach a staggering US$72.94bn.
It is further projected that this revenue will experience a steady annual growth rate (CAGR 2024-2029) of 6.11%, ultimately leading to a market volume of US$98.13bn by the year 2029.
When comparing the global market, United States is expected to generate the highest revenue, amounting to approximately US$136.00bn in 2024.
China is investing heavily in research and development to advance treatment options for cardiovascular diseases, aiming to become a global leader in this field.

Key regions: Germany, France, Japan, Europe, India

Market

Region

Region comparison

Currency

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on revenue received by hospitals from public or private sources, allocated to the country where the money is spent, including VAT if applicable.

Modeling approach / Market size:

Market sizes are determined by a bottom-up approach, based on a specific rationale for each market market. Next, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, public health spend, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.